Bioxcel Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bioxcel Therapeutics Inc 's ROA in the second quarter of 2026?
Bioxcel Therapeutics Inc recorded a cumulative net loss of $-71 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -181.93%.

However, within the Healthcare sector 842 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4492, from total ROA ranking in the first quarter of 2026 at 5157.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	26.17 %	-11.77 %	17.01 %	-8.67 %	-60.93 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-71	-75	-70	-68	-51
Return On Assets (TTM)	-181.93 %	-202.1 %	-181.97 %	-185.45 %	-134.64 %
BTAI's Total Ranking	# 4492	# 5157	# 4585	# 4559	# 4439
Total Assets (TTM) in million	32	34	45	45	26
Seq. Total Assets Change	-5.19 %	-24.15 %	0.47 %	74.65 %	-33.71 %
Seq. Net Income Change	-	-	-	-	-

BTAI's 5 Years Annual ROA >> Back to BTAI Management Effectiveness >> Compare BTAI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 399
Sector	# 843
Overall	# 4419

Return On Assets Statistics
High	Average	Low
-42.33 %	-97.64 %	-201.53 %
(Sep 30 2021)		(Mar 31 2026)

Financial Statements
Bioxcel Therapeutics Inc 's Assets	$ 32 million	BTAI's Balance sheet
Bioxcel Therapeutics Inc 's Income	$ -15 million	Quarterly BTAI's Income Statement
BTAI's Income by Division		See BTAI's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	17.01 %	-47.98 %	-64.2 %	-13.91 %	8.72 %
Total Assets in million	45	38	74	206	239
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-70	-60	-179	-166	-107
Annual Return On Assets	-155.81 %	-155.46 %	-242.94 %	-80.52 %	-44.72 %

BTAI's 5 Years Annual ROA >> Back to BTAI Management Effectiveness >> Compare BTAI ROA to its Competitors

More Return On Assets Ratios
BTAI's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BTAI's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BTAI's Competitors
Subscribers only: Roa for Bioxcel Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for BTAI's Customers

You may also want to know
BTAI's Roi	BTAI's Inventory Turnover Ratio	BTAI's Growth Rates	BTAI's Dividend Comparisons
	BTAI's Profitability Ratios	BTAI's Asset Turnover Ratio	BTAI's Dividend Growth
BTAI's Roe	BTAI's Valuation Ratios	BTAI's Financial Strength Ratios	BTAI's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:38:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.